Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs
305 Nevertheless, IR can be linked to a cluster of abnormal syndrome (Fig
Affected individuals are typically characterised by lipoatrophic diabetes, insulin resistance and hepatic steatosis ( Agonists of the glucagon-like peptide-1 receptor (GLP-1R) deliver significant beneficial effects both in treating type 2 diabetes and obesity ( Reports of the effects of GLP-1R agonists in individuals with inherited lipodystrophies are currently limited to only 3 case studies, and these examine FPLD but not CGL patients ( Here we used a well validated Bscl2 -null (seipin knockout) mouse model of CGL type 2 (CGL2) to examine the effectiveness of a GLP-1R agonist, in treating lipoatrophic diabetes, hepatic steatosis and hyperphagia in CGL to inform the adoption of this class of drugs for individuals with lipodystrophy
As a once-weekly subcutaneous injection, tirzepatide works by enhancing insulin secretion in response to meals, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system pathways
It uses the same active ingredient found in Ozempic